Antibiotic fidaxomicin is an RdRp inhibitor as a potential new therapeutic agent against Zika virus.

ABSTRACT:

Background

Zika virus (ZIKV) infection is a global health problem, and its complications, including congenital Zika syndrome and Guillain-Barré syndrome, constitute a continued threat to humans. Unfortunately, effective therapeutics against ZIKV infection are not available thus far.

Methods

We screened the compounds collection consisting of 1789 FDA-approved drugs by a computational docking method to obtain anti-ZIKV candidate compounds targeting ZIKV RNA-dependent RNA polymerase (RdRp). SPR (BIAcore) assay was employed to demonstrate the candidate compounds' direct binding to ZIKV RdRp, and polymerase activity assay was used to determine the inhibitory effect on ZIKV RdRp-catalyzed RNA synthesis. The antiviral effects on ZIKV in vitro and in vivo were detected in infected c

SUBMITTER: Yuan J 

PROVIDER: S-EPMC7392643 | biostudies-literature | 2020 Jul

REPOSITORIES: biostudies-literature